quantisnow
FeedTopReportsPricing
⌘K
Live feed
01:00:00·134d
PRRelease
Zealand Pharma A/S logo

Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

ZEAL· Zealand Pharma A/S
Health Care
Original source

Companies

  • ZEAL
    Zealand Pharma A/S
    Health Care

Recent analyst ratings

  • Mar 5UpdateBerenberg-
  • Aug 8UpdateMorgan Stanley-
  • Nov 16UpdateMorgan Stanley-
  • Jan 11UpdateJefferies-

Related

  • PR4d
    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
  • PR4d
    Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2026
  • PR9d
    Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
  • PR23d
    Total number of shares and voting rights in Zealand Pharma as of March 31, 2026
  • PR28d
    Resolutions from Zealand Pharma's Annual General Meeting 2026
  • PR30d
    Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation
  • PR35d
    Zealand Pharma increases its share capital as a result of the exercise of employee warrants
  • PR45d
    Zealand Pharma to participate in upcoming investor conferences in March 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022